Table of Content

1 Report Overview
1.1 Antihemophilic Factor Drug Definition
1.2 Market by Type
1.2.1 Global Antihemophilic Factor Drug Market Size Growth Rate by Type, 2018 VS 2024 VS 2034
1.2.2 250 IU
1.2.3 500 IU
1.2.4 1000 IU
1.2.5 1500 IU
1.2.6 2000 IU
1.2.7 3000 IU
1.2.8 4000 IU
1.2.9 Other potencies
1.3 Market Segment by Application
1.3.1 Global Antihemophilic Factor Drug Market Size Growth Rate by Application, 2018 VS 2024 VS 2034
1.3.2 Adult
1.3.3 Pediatric
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Antihemophilic Factor Drug Sales
2.1 Global Antihemophilic Factor Drug Revenue Estimates and Forecasts 2018-2034
2.2 Global Antihemophilic Factor Drug Revenue by Region: 2018 VS 2024 VS 2034
2.3 Global Antihemophilic Factor Drug Revenue by Region
2.3.1 Global Antihemophilic Factor Drug Revenue by Region (2018-2023)
2.3.2 Global Antihemophilic Factor Drug Revenue by Region (2024-2034)
2.4 Global Antihemophilic Factor Drug Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Antihemophilic Factor Drug Sales Quantity by Region: 2018 VS 2024 VS 2034
2.6 Global Antihemophilic Factor Drug Sales Quantity by Region
2.6.1 Global Antihemophilic Factor Drug Sales Quantity by Region (2018-2023)
2.6.2 Global Antihemophilic Factor Drug Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Antihemophilic Factor Drug Sales Quantity by Manufacturers
3.1.1 Global Antihemophilic Factor Drug Sales Quantity by Manufacturers (2018-2023)
3.1.2 Global Antihemophilic Factor Drug Sales Quantity Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Companies by Antihemophilic Factor Drug Sales in 2024
3.2 Global Antihemophilic Factor Drug Revenue by Manufacturers
3.2.1 Global Antihemophilic Factor Drug Revenue by Manufacturers (2018-2023)
3.2.2 Global Antihemophilic Factor Drug Revenue Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Antihemophilic Factor Drug Revenue in 2024
3.3 Global Antihemophilic Factor Drug Sales Price by Manufacturers
3.4 Global Key Players of Antihemophilic Factor Drug, Industry Ranking, 2021 VS 2024
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Antihemophilic Factor Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Antihemophilic Factor Drug, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Antihemophilic Factor Drug, Product Offered and Application
3.8 Global Key Manufacturers of Antihemophilic Factor Drug, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Antihemophilic Factor Drug Sales Quantity by Type
4.1.1 Global Antihemophilic Factor Drug Historical Sales Quantity by Type (2018-2023)
4.1.2 Global Antihemophilic Factor Drug Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Antihemophilic Factor Drug Sales Quantity Market Share by Type (2018-2034)
4.2 Global Antihemophilic Factor Drug Revenue by Type
4.2.1 Global Antihemophilic Factor Drug Historical Revenue by Type (2018-2023)
4.2.2 Global Antihemophilic Factor Drug Forecasted Revenue by Type (2024-2034)
4.2.3 Global Antihemophilic Factor Drug Revenue Market Share by Type (2018-2034)
4.3 Global Antihemophilic Factor Drug Price by Type
4.3.1 Global Antihemophilic Factor Drug Price by Type (2018-2023)
4.3.2 Global Antihemophilic Factor Drug Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Antihemophilic Factor Drug Sales Quantity by Application
5.1.1 Global Antihemophilic Factor Drug Historical Sales Quantity by Application (2018-2023)
5.1.2 Global Antihemophilic Factor Drug Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Antihemophilic Factor Drug Sales Quantity Market Share by Application (2018-2034)
5.2 Global Antihemophilic Factor Drug Revenue by Application
5.2.1 Global Antihemophilic Factor Drug Historical Revenue by Application (2018-2023)
5.2.2 Global Antihemophilic Factor Drug Forecasted Revenue by Application (2024-2034)
5.2.3 Global Antihemophilic Factor Drug Revenue Market Share by Application (2018-2034)
5.3 Global Antihemophilic Factor Drug Price by Application
5.3.1 Global Antihemophilic Factor Drug Price by Application (2018-2023)
5.3.2 Global Antihemophilic Factor Drug Price Forecast by Application (2024-2034)
6 North America
6.1 North America Antihemophilic Factor Drug Sales by Company
6.1.1 North America Antihemophilic Factor Drug Revenue by Company (2018-2023)
6.1.2 North America Antihemophilic Factor Drug Sales Quantity by Company (2018-2023)
6.2 North America Antihemophilic Factor Drug Market Size by Type
6.2.1 North America Antihemophilic Factor Drug Sales Quantity by Type (2018-2034)
6.2.2 North America Antihemophilic Factor Drug Revenue by Type (2018-2034)
6.3 North America Antihemophilic Factor Drug Market Size by Application
6.3.1 North America Antihemophilic Factor Drug Sales Quantity by Application (2018-2034)
6.3.2 North America Antihemophilic Factor Drug Revenue by Application (2018-2034)
6.4 North America Antihemophilic Factor Drug Market Size by Country
6.4.1 North America Antihemophilic Factor Drug Revenue by Country: 2018 VS 2024 VS 2034
6.4.2 North America Antihemophilic Factor Drug Revenue by Country (2018-2034)
6.4.3 North America Antihemophilic Factor Drug Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Antihemophilic Factor Drug Sales by Company
7.1.1 Europe Antihemophilic Factor Drug Sales Quantity by Company (2018-2023)
7.1.2 Europe Antihemophilic Factor Drug Revenue by Company (2018-2023)
7.2 Europe Antihemophilic Factor Drug Market Size by Type
7.2.1 Europe Antihemophilic Factor Drug Sales Quantity by Type (2018-2034)
7.2.2 Europe Antihemophilic Factor Drug Revenue by Type (2018-2034)
7.3 Europe Antihemophilic Factor Drug Market Size by Application
7.3.1 Europe Antihemophilic Factor Drug Sales Quantity by Application (2018-2034)
7.3.2 Europe Antihemophilic Factor Drug Revenue by Application (2018-2034)
7.4 Europe Antihemophilic Factor Drug Market Size by Country
7.4.1 Europe Antihemophilic Factor Drug Revenue by Country: 2018 VS 2024 VS 2034
7.4.2 Europe Antihemophilic Factor Drug Revenue by Country (2018-2034)
7.4.3 Europe Antihemophilic Factor Drug Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Antihemophilic Factor Drug Sales by Company
8.1.1 China Antihemophilic Factor Drug Sales Quantity by Company (2018-2023)
8.1.2 China Antihemophilic Factor Drug Revenue by Company (2018-2023)
8.2 China Antihemophilic Factor Drug Market Size by Type
8.2.1 China Antihemophilic Factor Drug Sales Quantity by Type (2018-2034)
8.2.2 China Antihemophilic Factor Drug Revenue by Type (2018-2034)
8.3 China Antihemophilic Factor Drug Market Size by Application
8.3.1 China Antihemophilic Factor Drug Sales Quantity by Application (2018-2034)
8.3.2 China Antihemophilic Factor Drug Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Antihemophilic Factor Drug Sales by Company
9.1.1 APAC Antihemophilic Factor Drug Sales Quantity by Company (2018-2023)
9.1.2 APAC Antihemophilic Factor Drug Revenue by Company (2018-2023)
9.2 APAC Antihemophilic Factor Drug Market Size by Type
9.2.1 APAC Antihemophilic Factor Drug Sales Quantity by Type (2018-2034)
9.2.2 APAC Antihemophilic Factor Drug Revenue by Type (2018-2034)
9.3 APAC Antihemophilic Factor Drug Market Size by Application
9.3.1 APAC Antihemophilic Factor Drug Sales Quantity by Application (2018-2034)
9.3.2 APAC Antihemophilic Factor Drug Revenue by Application (2018-2034)
9.4 APAC Antihemophilic Factor Drug Market Size by Region
9.4.1 APAC Antihemophilic Factor Drug Revenue by Region: 2018 VS 2024 VS 2034
9.4.2 APAC Antihemophilic Factor Drug Revenue by Region (2018-2034)
9.4.3 APAC Antihemophilic Factor Drug Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Antihemophilic Factor Drug Sales by Company
10.1.1 Middle East, Africa and Latin America Antihemophilic Factor Drug Sales Quantity by Company (2018-2023)
10.1.2 Middle East, Africa and Latin America Antihemophilic Factor Drug Revenue by Company (2018-2023)
10.2 Middle East, Africa and Latin America Antihemophilic Factor Drug Market Size by Type
10.2.1 Middle East, Africa and Latin America Antihemophilic Factor Drug Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Antihemophilic Factor Drug Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Antihemophilic Factor Drug Market Size by Application
10.3.1 Middle East, Africa and Latin America Antihemophilic Factor Drug Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Antihemophilic Factor Drug Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Antihemophilic Factor Drug Market Size by Country
10.4.1 Middle East, Africa and Latin America Antihemophilic Factor Drug Revenue by Country: 2018 VS 2024 VS 2034
10.4.2 Middle East, Africa and Latin America Antihemophilic Factor Drug Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Antihemophilic Factor Drug Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Bayer
11.1.1 Bayer Company Information
11.1.2 Bayer Overview
11.1.3 Bayer Antihemophilic Factor Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.1.4 Bayer Antihemophilic Factor Drug Products and Services
11.1.5 Bayer Antihemophilic Factor Drug SWOT Analysis
11.1.6 Bayer Recent Developments
11.2 Takeda
11.2.1 Takeda Company Information
11.2.2 Takeda Overview
11.2.3 Takeda Antihemophilic Factor Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.2.4 Takeda Antihemophilic Factor Drug Products and Services
11.2.5 Takeda Antihemophilic Factor Drug SWOT Analysis
11.2.6 Takeda Recent Developments
11.3 Novo Nordisk
11.3.1 Novo Nordisk Company Information
11.3.2 Novo Nordisk Overview
11.3.3 Novo Nordisk Antihemophilic Factor Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.3.4 Novo Nordisk Antihemophilic Factor Drug Products and Services
11.3.5 Novo Nordisk Antihemophilic Factor Drug SWOT Analysis
11.3.6 Novo Nordisk Recent Developments
11.4 Pfizer
11.4.1 Pfizer Company Information
11.4.2 Pfizer Overview
11.4.3 Pfizer Antihemophilic Factor Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.4.4 Pfizer Antihemophilic Factor Drug Products and Services
11.4.5 Pfizer Antihemophilic Factor Drug SWOT Analysis
11.4.6 Pfizer Recent Developments
11.5 Grifols
11.5.1 Grifols Company Information
11.5.2 Grifols Overview
11.5.3 Grifols Antihemophilic Factor Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.5.4 Grifols Antihemophilic Factor Drug Products and Services
11.5.5 Grifols Antihemophilic Factor Drug SWOT Analysis
11.5.6 Grifols Recent Developments
11.6 CSL Behring
11.6.1 CSL Behring Company Information
11.6.2 CSL Behring Overview
11.6.3 CSL Behring Antihemophilic Factor Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.6.4 CSL Behring Antihemophilic Factor Drug Products and Services
11.6.5 CSL Behring Antihemophilic Factor Drug SWOT Analysis
11.6.6 CSL Behring Recent Developments
11.7 Sanofi
11.7.1 Sanofi Company Information
11.7.2 Sanofi Overview
11.7.3 Sanofi Antihemophilic Factor Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.7.4 Sanofi Antihemophilic Factor Drug Products and Services
11.7.5 Sanofi Antihemophilic Factor Drug SWOT Analysis
11.7.6 Sanofi Recent Developments
11.8 Cigna
11.8.1 Cigna Company Information
11.8.2 Cigna Overview
11.8.3 Cigna Antihemophilic Factor Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.8.4 Cigna Antihemophilic Factor Drug Products and Services
11.8.5 Cigna Antihemophilic Factor Drug SWOT Analysis
11.8.6 Cigna Recent Developments
11.9 Octapharma
11.9.1 Octapharma Company Information
11.9.2 Octapharma Overview
11.9.3 Octapharma Antihemophilic Factor Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.9.4 Octapharma Antihemophilic Factor Drug Products and Services
11.9.5 Octapharma Antihemophilic Factor Drug SWOT Analysis
11.9.6 Octapharma Recent Developments
11.10 GC Pharma
11.10.1 GC Pharma Company Information
11.10.2 GC Pharma Overview
11.10.3 GC Pharma Antihemophilic Factor Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.10.4 GC Pharma Antihemophilic Factor Drug Products and Services
11.10.5 GC Pharma Antihemophilic Factor Drug SWOT Analysis
11.10.6 GC Pharma Recent Developments
11.11 Hualan Biological Engineering
11.11.1 Hualan Biological Engineering Company Information
11.11.2 Hualan Biological Engineering Overview
11.11.3 Hualan Biological Engineering Antihemophilic Factor Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.11.4 Hualan Biological Engineering Antihemophilic Factor Drug Products and Services
11.11.5 Hualan Biological Engineering Recent Developments
11.12 Shanghai RAAS blood products
11.12.1 Shanghai RAAS blood products Company Information
11.12.2 Shanghai RAAS blood products Overview
11.12.3 Shanghai RAAS blood products Antihemophilic Factor Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.12.4 Shanghai RAAS blood products Antihemophilic Factor Drug Products and Services
11.12.5 Shanghai RAAS blood products Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Antihemophilic Factor Drug Value Chain Analysis
12.2 Antihemophilic Factor Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Antihemophilic Factor Drug Production Mode & Process
12.4 Antihemophilic Factor Drug Sales and Marketing
12.4.1 Antihemophilic Factor Drug Sales Channels
12.4.2 Antihemophilic Factor Drug Distributors
12.5 Antihemophilic Factor Drug Customers
13 Market Dynamics
13.1 Antihemophilic Factor Drug Industry Trends
13.2 Antihemophilic Factor Drug Market Drivers
13.3 Antihemophilic Factor Drug Market Challenges
13.4 Antihemophilic Factor Drug Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Antihemophilic Factor Drug Market Size Growth Rate (CAGR) by Type, 2018 VS 2024 VS 2034 (US$ Million)
Table 2. Major Manufacturers of 250 IU
Table 3. Major Manufacturers of 500 IU
Table 4. Major Manufacturers of 1000 IU
Table 5. Major Manufacturers of 1500 IU
Table 6. Major Manufacturers of 2000 IU
Table 7. Major Manufacturers of 3000 IU
Table 8. Major Manufacturers of 4000 IU
Table 9. Major Manufacturers of Other potencies
Table 10. Global Antihemophilic Factor Drug Market Size Growth Rate (CAGR) by Application, 2018 VS 2024 VS 2034 (US$ Million)
Table 11. Global Antihemophilic Factor Drug Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 12. Global Antihemophilic Factor Drug Revenue by Region (2018-2023) & (US$ Million)
Table 13. Global Antihemophilic Factor Drug Revenue Market Share by Region (2018-2023)
Table 14. Global Antihemophilic Factor Drug Revenue by Region (2024-2034) & (US$ Million)
Table 15. Global Antihemophilic Factor Drug Revenue Market Share by Region (2024-2034)
Table 16. Global Antihemophilic Factor Drug Sales Quantity by Region: 2018 VS 2024 VS 2034 (K Units)
Table 17. Global Antihemophilic Factor Drug Sales by Region (2018-2023) & (K Units)
Table 18. Global Antihemophilic Factor Drug Sales Market Share by Region (2018-2023)
Table 19. Global Antihemophilic Factor Drug Sales by Region (2024-2034) & (K Units)
Table 20. Global Antihemophilic Factor Drug Sales Market Share by Region (2024-2034)
Table 21. Global Antihemophilic Factor Drug Sales Quantity by Manufacturers (2018-2023) & (K Units)
Table 22. Global Antihemophilic Factor Drug Sales Quantity Share by Manufacturers (2018-2023)
Table 23. Global Antihemophilic Factor Drug Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 24. Global Antihemophilic Factor Drug Revenue Share by Manufacturers (2018-2023)
Table 25. Global Antihemophilic Factor Drug Price by Manufacturers 2018-2023 (USD/Unit)
Table 26. Global Key Players of Antihemophilic Factor Drug, Industry Ranking, 2021 VS 2024
Table 27. Global Antihemophilic Factor Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 28. Global Antihemophilic Factor Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antihemophilic Factor Drug as of 2024)
Table 29. Global Key Manufacturers of Antihemophilic Factor Drug, Manufacturing Base Distribution and Headquarters
Table 30. Global Key Manufacturers of Antihemophilic Factor Drug, Product Offered and Application
Table 31. Global Key Manufacturers of Antihemophilic Factor Drug, Date of Enter into This Industry
Table 32. Mergers & Acquisitions, Expansion Plans
Table 33. Global Antihemophilic Factor Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 34. Global Antihemophilic Factor Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 35. Global Antihemophilic Factor Drug Sales Quantity Share by Type (2018-2023)
Table 36. Global Antihemophilic Factor Drug Sales Quantity Share by Type (2024-2034)
Table 37. Global Antihemophilic Factor Drug Revenue by Type (2018-2023) & (US$ Million)
Table 38. Global Antihemophilic Factor Drug Revenue by Type (2024-2034) & (US$ Million)
Table 39. Global Antihemophilic Factor Drug Revenue Share by Type (2018-2023)
Table 40. Global Antihemophilic Factor Drug Revenue Share by Type (2024-2034)
Table 41. Antihemophilic Factor Drug Price by Type (2018-2023) & (USD/Unit)
Table 42. Global Antihemophilic Factor Drug Price Forecast by Type (2024-2034) & (USD/Unit)
Table 43. Global Antihemophilic Factor Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 44. Global Antihemophilic Factor Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 45. Global Antihemophilic Factor Drug Sales Quantity Share by Application (2018-2023)
Table 46. Global Antihemophilic Factor Drug Sales Quantity Share by Application (2024-2034)
Table 47. Global Antihemophilic Factor Drug Revenue by Application (2018-2023) & (US$ Million)
Table 48. Global Antihemophilic Factor Drug Revenue by Application (2024-2034) & (US$ Million)
Table 49. Global Antihemophilic Factor Drug Revenue Share by Application (2018-2023)
Table 50. Global Antihemophilic Factor Drug Revenue Share by Application (2024-2034)
Table 51. Antihemophilic Factor Drug Price by Application (2018-2023) & (USD/Unit)
Table 52. Global Antihemophilic Factor Drug Price Forecast by Application (2024-2034) & (USD/Unit)
Table 53. North America Antihemophilic Factor Drug Revenue by Company (2018-2023) & (US$ Million)
Table 54. North America Antihemophilic Factor Drug Sales Quantity by Company (2018-2023) & (K Units)
Table 55. North America Antihemophilic Factor Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 56. North America Antihemophilic Factor Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 57. North America Antihemophilic Factor Drug Revenue by Type (2018-2023) & (US$ Million)
Table 58. North America Antihemophilic Factor Drug Revenue by Type (2024-2034) & (US$ Million)
Table 59. North America Antihemophilic Factor Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 60. North America Antihemophilic Factor Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 61. North America Antihemophilic Factor Drug Revenue by Application (2018-2023) & (US$ Million)
Table 62. North America Antihemophilic Factor Drug Revenue by Application (2024-2034) & (US$ Million)
Table 63. North America Antihemophilic Factor Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 64. North America Antihemophilic Factor Drug Revenue by Country (2018-2023) & (US$ Million)
Table 65. North America Antihemophilic Factor Drug Revenue by Country (2024-2034) & (US$ Million)
Table 66. North America Antihemophilic Factor Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 67. North America Antihemophilic Factor Drug Sales Quantity by Country (2024-2034) & (K Units)
Table 68. Europe Antihemophilic Factor Drug Sales Quantity by Company (2018-2023) & (K Units)
Table 69. Europe Antihemophilic Factor Drug Revenue by Company (2018-2023) & (US$ Million)
Table 70. Europe Antihemophilic Factor Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 71. Europe Antihemophilic Factor Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 72. Europe Antihemophilic Factor Drug Revenue by Type (2018-2023) & (US$ Million)
Table 73. Europe Antihemophilic Factor Drug Revenue by Type (2024-2034) & (US$ Million)
Table 74. Europe Antihemophilic Factor Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 75. Europe Antihemophilic Factor Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 76. Europe Antihemophilic Factor Drug Revenue by Application (2018-2023) & (US$ Million)
Table 77. Europe Antihemophilic Factor Drug Revenue by Application (2024-2034) & (US$ Million)
Table 78. Europe Antihemophilic Factor Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 79. Europe Antihemophilic Factor Drug Revenue by Country (2018-2023) & (US$ Million)
Table 80. Europe Antihemophilic Factor Drug Revenue by Country (2024-2034) & (US$ Million)
Table 81. Europe Antihemophilic Factor Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 82. Europe Antihemophilic Factor Drug Sales Quantity by Country (2024-2034) & (K Units)
Table 83. China Antihemophilic Factor Drug Sales Quantity by Company (2018-2023) & (K Units)
Table 84. China Antihemophilic Factor Drug Revenue by Company (2018-2023) & (US$ Million)
Table 85. China Antihemophilic Factor Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 86. China Antihemophilic Factor Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 87. China Antihemophilic Factor Drug Revenue by Type (2018-2023) & (US$ Million)
Table 88. China Antihemophilic Factor Drug Revenue by Type (2024-2034) & (US$ Million)
Table 89. China Antihemophilic Factor Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 90. China Antihemophilic Factor Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 91. China Antihemophilic Factor Drug Revenue by Application (2018-2023) & (US$ Million)
Table 92. China Antihemophilic Factor Drug Revenue by Application (2024-2034) & (US$ Million)
Table 93. APAC Antihemophilic Factor Drug Sales Quantity by Company (2018-2023) & (K Units)
Table 94. APAC Antihemophilic Factor Drug Revenue by Company (2018-2023) & (US$ Million)
Table 95. APAC Antihemophilic Factor Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 96. APAC Antihemophilic Factor Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 97. APAC Antihemophilic Factor Drug Revenue by Type (2018-2023) & (US$ Million)
Table 98. APAC Antihemophilic Factor Drug Revenue by Type (2024-2034) & (US$ Million)
Table 99. APAC Antihemophilic Factor Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 100. APAC Antihemophilic Factor Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 101. APAC Antihemophilic Factor Drug Revenue by Application (2018-2023) & (US$ Million)
Table 102. APAC Antihemophilic Factor Drug Revenue by Application (2024-2034) & (US$ Million)
Table 103. APAC Antihemophilic Factor Drug Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 104. APAC Antihemophilic Factor Drug Revenue by Region (2018-2023) & (US$ Million)
Table 105. APAC Antihemophilic Factor Drug Revenue by Region (2024-2034) & (US$ Million)
Table 106. APAC Antihemophilic Factor Drug Sales Quantity by Region (2018-2023) & (K Units)
Table 107. APAC Antihemophilic Factor Drug Sales Quantity by Region (2024-2034) & (K Units)
Table 108. Middle East, Africa and Latin America Antihemophilic Factor Drug Sales Quantity by Company (2018-2023) & (K Units)
Table 109. Middle East, Africa and Latin America Antihemophilic Factor Drug Revenue by Company (2018-2023) & (US$ Million)
Table 110. Middle East, Africa and Latin America Antihemophilic Factor Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 111. Middle East, Africa and Latin America Antihemophilic Factor Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 112. Middle East, Africa and Latin America Antihemophilic Factor Drug Revenue by Type (2018-2023) & (US$ Million)
Table 113. Middle East, Africa and Latin America Antihemophilic Factor Drug Revenue by Type (2024-2034) & (US$ Million)
Table 114. Middle East, Africa and Latin America Antihemophilic Factor Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 115. Middle East, Africa and Latin America Antihemophilic Factor Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 116. Middle East, Africa and Latin America Antihemophilic Factor Drug Revenue by Application (2018-2023) & (US$ Million)
Table 117. Middle East, Africa and Latin America Antihemophilic Factor Drug Revenue by Application (2024-2034) & (US$ Million)
Table 118. Middle East, Africa and Latin America Antihemophilic Factor Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 119. Middle East, Africa and Latin America Antihemophilic Factor Drug Revenue by Country (2018-2023) & (US$ Million)
Table 120. Middle East, Africa and Latin America Antihemophilic Factor Drug Revenue by Country (2024-2034) & (US$ Million)
Table 121. Middle East, Africa and Latin America Antihemophilic Factor Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 122. Middle East, Africa and Latin America Antihemophilic Factor Drug Sales Quantity by Country (2024-2034) & (K Units)
Table 123. Bayer Company Information
Table 124. Bayer Description and Overview
Table 125. Bayer Antihemophilic Factor Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 126. Bayer Antihemophilic Factor Drug Product and Services
Table 127. Bayer Antihemophilic Factor Drug SWOT Analysis
Table 128. Bayer Recent Developments
Table 129. Takeda Company Information
Table 130. Takeda Description and Overview
Table 131. Takeda Antihemophilic Factor Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 132. Takeda Antihemophilic Factor Drug Product and Services
Table 133. Takeda Antihemophilic Factor Drug SWOT Analysis
Table 134. Takeda Recent Developments
Table 135. Novo Nordisk Company Information
Table 136. Novo Nordisk Description and Overview
Table 137. Novo Nordisk Antihemophilic Factor Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 138. Novo Nordisk Antihemophilic Factor Drug Product and Services
Table 139. Novo Nordisk Antihemophilic Factor Drug SWOT Analysis
Table 140. Novo Nordisk Recent Developments
Table 141. Pfizer Company Information
Table 142. Pfizer Description and Overview
Table 143. Pfizer Antihemophilic Factor Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 144. Pfizer Antihemophilic Factor Drug Product and Services
Table 145. Pfizer Antihemophilic Factor Drug SWOT Analysis
Table 146. Pfizer Recent Developments
Table 147. Grifols Company Information
Table 148. Grifols Description and Overview
Table 149. Grifols Antihemophilic Factor Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 150. Grifols Antihemophilic Factor Drug Product and Services
Table 151. Grifols Antihemophilic Factor Drug SWOT Analysis
Table 152. Grifols Recent Developments
Table 153. CSL Behring Company Information
Table 154. CSL Behring Description and Overview
Table 155. CSL Behring Antihemophilic Factor Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 156. CSL Behring Antihemophilic Factor Drug Product and Services
Table 157. CSL Behring Antihemophilic Factor Drug SWOT Analysis
Table 158. CSL Behring Recent Developments
Table 159. Sanofi Company Information
Table 160. Sanofi Description and Overview
Table 161. Sanofi Antihemophilic Factor Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 162. Sanofi Antihemophilic Factor Drug Product and Services
Table 163. Sanofi Antihemophilic Factor Drug SWOT Analysis
Table 164. Sanofi Recent Developments
Table 165. Cigna Company Information
Table 166. Cigna Description and Overview
Table 167. Cigna Antihemophilic Factor Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 168. Cigna Antihemophilic Factor Drug Product and Services
Table 169. Cigna Antihemophilic Factor Drug SWOT Analysis
Table 170. Cigna Recent Developments
Table 171. Octapharma Company Information
Table 172. Octapharma Description and Overview
Table 173. Octapharma Antihemophilic Factor Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 174. Octapharma Antihemophilic Factor Drug Product and Services
Table 175. Octapharma Antihemophilic Factor Drug SWOT Analysis
Table 176. Octapharma Recent Developments
Table 177. GC Pharma Company Information
Table 178. GC Pharma Description and Overview
Table 179. GC Pharma Antihemophilic Factor Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 180. GC Pharma Antihemophilic Factor Drug Product and Services
Table 181. GC Pharma Antihemophilic Factor Drug SWOT Analysis
Table 182. GC Pharma Recent Developments
Table 183. Hualan Biological Engineering Company Information
Table 184. Hualan Biological Engineering Description and Overview
Table 185. Hualan Biological Engineering Antihemophilic Factor Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 186. Hualan Biological Engineering Antihemophilic Factor Drug Product and Services
Table 187. Hualan Biological Engineering Recent Developments
Table 188. Shanghai RAAS blood products Company Information
Table 189. Shanghai RAAS blood products Description and Overview
Table 190. Shanghai RAAS blood products Antihemophilic Factor Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 191. Shanghai RAAS blood products Antihemophilic Factor Drug Product and Services
Table 192. Shanghai RAAS blood products Recent Developments
Table 193. Key Raw Materials Lists
Table 194. Raw Materials Key Suppliers Lists
Table 195. Antihemophilic Factor Drug Distributors List
Table 196. Antihemophilic Factor Drug Customers List
Table 197. Antihemophilic Factor Drug Market Trends
Table 198. Antihemophilic Factor Drug Market Drivers
Table 199. Antihemophilic Factor Drug Market Challenges
Table 200. Antihemophilic Factor Drug Market Restraints
Table 201. Research Programs/Design for This Report
Table 202. Key Data Information from Secondary Sources
Table 203. Key Data Information from Primary Sources
List of Figures
Figure 1. Antihemophilic Factor Drug Product Picture
Figure 2. Global Antihemophilic Factor Drug Market Size Growth Rate by Type, 2018 VS 2024 VS 2034 (US$ Million)
Figure 3. Global Antihemophilic Factor Drug Market Share by Type in 2024 & 2034
Figure 4. 250 IU Product Picture
Figure 5. 500 IU Product Picture
Figure 6. 1000 IU Product Picture
Figure 7. 1500 IU Product Picture
Figure 8. 2000 IU Product Picture
Figure 9. 3000 IU Product Picture
Figure 10. 4000 IU Product Picture
Figure 11. Other potencies Product Picture
Figure 12. Global Antihemophilic Factor Drug Market Size Growth Rate by Application, 2018 VS 2024 VS 2034 (US$ Million)
Figure 13. Global Antihemophilic Factor Drug Market Share by Application in 2024 & 2034
Figure 14. Adult
Figure 15. Pediatric
Figure 16. Antihemophilic Factor Drug Report Years Considered
Figure 17. Global Antihemophilic Factor Drug Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 18. Global Antihemophilic Factor Drug Revenue 2018-2034 (US$ Million)
Figure 19. Global Antihemophilic Factor Drug Revenue Market Share by Region in Percentage: 2024 Versus 2034
Figure 20. Global Antihemophilic Factor Drug Sales Quantity 2018-2034 (K Units)
Figure 21. Global Antihemophilic Factor Drug Sales Quantity Market Share by Region (2018-2023)
Figure 22. Global Antihemophilic Factor Drug Sales Quantity Market Share by Region (2024-2034)
Figure 23. North America Antihemophilic Factor Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 24. North America Antihemophilic Factor Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 25. Europe Antihemophilic Factor Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 26. Europe Antihemophilic Factor Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 27. China Antihemophilic Factor Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 28. China Antihemophilic Factor Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 29. APAC Antihemophilic Factor Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 30. APAC Antihemophilic Factor Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 31. Middle East, Africa and Latin America Antihemophilic Factor Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 32. Middle East, Africa and Latin America Antihemophilic Factor Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 33. The Top 10 and Top 5 Players Market Share by Antihemophilic Factor Drug Sales Quantity in 2024
Figure 34. The Top 10 and Top 5 Players Market Share by Antihemophilic Factor Drug Revenue in 2024
Figure 35. Antihemophilic Factor Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2024
Figure 36. Global Antihemophilic Factor Drug Sales Quantity Market Share by Type (2018-2034)
Figure 37. Global Antihemophilic Factor Drug Revenue Market Share by Type (2018-2034)
Figure 38. Global Antihemophilic Factor Drug Sales Quantity Market Share by Application (2018-2034)
Figure 39. Global Antihemophilic Factor Drug Revenue Market Share by Application (2018-2034)
Figure 40. North America Antihemophilic Factor Drug Revenue Market Share by Company in 2024
Figure 41. North America Antihemophilic Factor Drug Sales Quantity Market Share by Company in 2024
Figure 42. North America Antihemophilic Factor Drug Sales Quantity Market Share by Type (2018-2034)
Figure 43. North America Antihemophilic Factor Drug Revenue Market Share by Type (2018-2034)
Figure 44. North America Antihemophilic Factor Drug Sales Quantity Market Share by Application (2018-2034)
Figure 45. North America Antihemophilic Factor Drug Revenue Market Share by Application (2018-2034)
Figure 46. North America Antihemophilic Factor Drug Revenue Share by Country (2018-2034)
Figure 47. North America Antihemophilic Factor Drug Sales Quantity Share by Country (2018-2034)
Figure 48. U.S. Antihemophilic Factor Drug Revenue (2018-2034) & (US$ Million)
Figure 49. Canada Antihemophilic Factor Drug Revenue (2018-2034) & (US$ Million)
Figure 50. Europe Antihemophilic Factor Drug Sales Quantity Market Share by Company in 2024
Figure 51. Europe Antihemophilic Factor Drug Revenue Market Share by Company in 2024
Figure 52. Europe Antihemophilic Factor Drug Sales Quantity Market Share by Type (2018-2034)
Figure 53. Europe Antihemophilic Factor Drug Revenue Market Share by Type (2018-2034)
Figure 54. Europe Antihemophilic Factor Drug Sales Quantity Market Share by Application (2018-2034)
Figure 55. Europe Antihemophilic Factor Drug Revenue Market Share by Application (2018-2034)
Figure 56. Europe Antihemophilic Factor Drug Revenue Share by Country (2018-2034)
Figure 57. Europe Antihemophilic Factor Drug Sales Quantity Share by Country (2018-2034)
Figure 58. Germany Antihemophilic Factor Drug Revenue (2018-2034) & (US$ Million)
Figure 59. France Antihemophilic Factor Drug Revenue (2018-2034) & (US$ Million)
Figure 60. U.K. Antihemophilic Factor Drug Revenue (2018-2034) & (US$ Million)
Figure 61. Italy Antihemophilic Factor Drug Revenue (2018-2034) & (US$ Million)
Figure 62. Russia Antihemophilic Factor Drug Revenue (2018-2034) & (US$ Million)
Figure 63. China Antihemophilic Factor Drug Sales Quantity Market Share by Company in 2024
Figure 64. China Antihemophilic Factor Drug Revenue Market Share by Company in 2024
Figure 65. China Antihemophilic Factor Drug Sales Quantity Market Share by Type (2018-2034)
Figure 66. China Antihemophilic Factor Drug Revenue Market Share by Type (2018-2034)
Figure 67. China Antihemophilic Factor Drug Sales Quantity Market Share by Application (2018-2034)
Figure 68. China Antihemophilic Factor Drug Revenue Market Share by Application (2018-2034)
Figure 69. APAC Antihemophilic Factor Drug Sales Quantity Market Share by Company in 2024
Figure 70. APAC Antihemophilic Factor Drug Revenue Market Share by Company in 2024
Figure 71. APAC Antihemophilic Factor Drug Sales Quantity Market Share by Type (2018-2034)
Figure 72. APAC Antihemophilic Factor Drug Revenue Market Share by Type (2018-2034)
Figure 73. APAC Antihemophilic Factor Drug Sales Quantity Market Share by Application (2018-2034)
Figure 74. APAC Antihemophilic Factor Drug Revenue Market Share by Application (2018-2034)
Figure 75. APAC Antihemophilic Factor Drug Revenue Share by Region (2018-2034)
Figure 76. APAC Antihemophilic Factor Drug Sales Quantity Share by Region (2018-2034)
Figure 77. Japan Antihemophilic Factor Drug Revenue (2018-2034) & (US$ Million)
Figure 78. South Korea Antihemophilic Factor Drug Revenue (2018-2034) & (US$ Million)
Figure 79. China Taiwan Antihemophilic Factor Drug Revenue (2018-2034) & (US$ Million)
Figure 80. Southeast Asia Antihemophilic Factor Drug Revenue (2018-2034) & (US$ Million)
Figure 81. India Antihemophilic Factor Drug Revenue (2018-2034) & (US$ Million)
Figure 82. Middle East, Africa and Latin America Antihemophilic Factor Drug Sales Quantity Market Share by Company in 2024
Figure 83. Middle East, Africa and Latin America Antihemophilic Factor Drug Revenue Market Share by Company in 2024
Figure 84. Middle East, Africa and Latin America Antihemophilic Factor Drug Sales Quantity Market Share by Type (2018-2034)
Figure 85. Middle East, Africa and Latin America Antihemophilic Factor Drug Revenue Market Share by Type (2018-2034)
Figure 86. Middle East, Africa and Latin America Antihemophilic Factor Drug Sales Quantity Market Share by Application (2018-2034)
Figure 87. Middle East, Africa and Latin America Antihemophilic Factor Drug Revenue Market Share by Application (2018-2034)
Figure 88. Middle East, Africa and Latin America Antihemophilic Factor Drug Sales Quantity Share by Country (2018-2034)
Figure 89. Middle East, Africa and Latin America Antihemophilic Factor Drug Revenue Share by Country (2018-2034)
Figure 90. Brazil Antihemophilic Factor Drug Revenue (2018-2034) & (US$ Million)
Figure 91. Mexico Antihemophilic Factor Drug Revenue (2018-2034) & (US$ Million)
Figure 92. Turkey Antihemophilic Factor Drug Revenue (2018-2034) & (US$ Million)
Figure 93. Israel Antihemophilic Factor Drug Revenue (2018-2034) & (US$ Million)
Figure 94. GCC Countries Antihemophilic Factor Drug Revenue (2018-2034) & (US$ Million)
Figure 95. Antihemophilic Factor Drug Value Chain
Figure 96. Antihemophilic Factor Drug Production Process
Figure 97. Channels of Distribution (Direct Vs Distribution)
Figure 98. Distributors Profiles
Figure 99. Bottom-up and Top-down Approaches for This Report
Figure 100. Data Triangulation
Figure 101. Key Executives Interviewed